

News Release

Biofrontera starts Sales and Marketing of Ameluz® in Spain

- **Key Account Manager transfers from Allergan to Biofrontera**
- **Biofrontera will capture full margin of Ameluz® sales with immediate effect**
- **International launch event with leading dermatologists in Valencia – 27/28 March**

Leverkusen, Germany, 25 March 2015 – Biofrontera AG (FSE: B8F), the biopharmaceutical company focusing on skin cancer, has now taken over marketing and sales activities for Ameluz® and BF-RhodoLED® in Spain as planned in line with its announcement made on 7 November 2014. Previously, these functions were performed by distribution partner Allergan Pharmaceuticals.

The successful transition has been prepared over several months in cooperation with Allergan. In addition, Biofrontera is pleased to announce that Antonio Lopez Belda, former Key Account Manager for dermatology at Allergan, has transferred to Biofrontera, with immediate effect. Mr. Lopez led the launch of Ameluz in Spain and has successfully developed the market since. This will allow for continuity with all established contacts within hospitals and physicians.

"Spain is one of the most important European markets for photodynamic therapy," said Prof. Dr. Hermann Lübbert, CEO of Biofrontera. "In the new structure, we can now collect the entire margin of the Ameluz® sales for Biofrontera. Thus, our profitability in Spain will increase significantly. It is anticipated that the additional investment in sales and marketing should pay off within one year."

The new Biofrontera subsidiary will be named 'Biofrontera Pharma GmbH, sucursal en España' and is based in Cornellá de Llobregat near Barcelona. In the current year Biofrontera expects sales in the mid six-digit Euro range in Spain.

On the occasion of the launch, Biofrontera will hold an international symposium in Valencia from March 27 to 28, and expects some 50 dermatologists from all over Spain to attend the event.

Ends

News Release

Enquiries, please contact:

Biofrontera AG	+49 (0) 214 87 63 2 0
Prof. Hermann Lübbert, Chief Executive Officer	press@biofrontera.com
Thomas Schaffer, Chief Financial Officer	www.biofrontera.com
IR Germany: Brainwell Asset Solutions	+49 (0) 152 08931514
Jürgen Benker	
Nomad and Broker: Shore Capital	+44(0) 20 7408 4090
Bidhi Bhoma / Toby Gibbs	
IR UK: Seton Services	+44(0) 20 7603 6797
Toni Vallen	
Financial PR: Gable Communications	+44(0) 20 7193 7463
John Bick	+44 (0)7872 061007

Background:

The **Biofrontera Group** (FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising in the development, sale and distribution of drugs and medical cosmetics for the care and treatment of skin diseases. Biofrontera's most important product is **Ameluz**[®], a prescription drug which is approved in Europe for the treatment of mild and moderate actinic keratosis (superficial skin cancer) with photodynamic therapy (light therapy). Biofrontera is the first German pharmaceutical start-up company to obtain centralised approval for a drug it has developed itself. The company also plans for Ameluz[®] to be approved for basal cell carcinoma and is currently preparing for approval in other countries, especially in the largest pharmaceutical market in the world, the United States.

The company also markets the Belixos[®] dermatological range of cosmetics. Belixos[®] products contain combinations of active substances extracted from plants, relieve itching and redness and are used for the regenerative care of chronic skin conditions such as atopic dermatitis or psoriasis. At the moment, Belixos[®] cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the Chairman of the company's Management Board, and has its headquarters in Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.